
    
      The total duration per patient is at least 3 years and up to 5 years and 3 months. This
      includes up to approximately two month of screening, 52 weeks of primary analysis period, up
      to 4 years and 3 months of extension treatment period, an end-of- study visit within 2 weeks
      of the last treatment, and a safety follow-up 30 to 37 days after the last treatment.
    
  